Synthetic lethality is a concept from genetics where two gene mutations are each harmless on their own, but lethal when they occur together in the same cell. It has become one of the most important strategies in modern cancer treatment because it offers a way to kill cancer cells while leaving healthy cells intact. The idea is deceptively simple: if a cancer cell already has one broken gene, you can design a drug that disables the partner gene, and only the cancer cell dies.
The Basic Logic
Your cells have built-in redundancy. If one system for repairing DNA breaks down, a backup system picks up the slack. Synthetic lethality exploits this by targeting both systems at once. In a healthy cell, knocking out one repair pathway isn’t a problem because the backup still works. But cancer cells often already have one pathway broken due to a mutation. A drug that blocks the backup pathway leaves those cells with no way to fix their DNA, and they die. Healthy cells, which still have both pathways intact, survive the drug just fine.
The National Cancer Institute defines it as a situation in which mutations in two genes together cause cell death, but a mutation in either gene alone does not. “Synthetic” here comes from the ancient Greek meaning of combining two things to create something new. In this case, combining two genetic disruptions creates a new outcome: death for that specific cell.
How It Was Discovered
The phenomenon was first observed by American geneticist Calvin Bridges in the early 20th century. Working with fruit flies, he noticed that certain gene combinations were lethal even though flies carrying either mutation alone were perfectly viable. About 20 years later, his colleague Theodore Dobzhansky saw the same pattern in a different fruit fly species and gave it the name “synthetic lethality.” For decades it remained a curiosity of genetics research. It wasn’t until the 2000s that scientists figured out how to turn this observation into cancer drugs.
PARP Inhibitors: The First Major Success
The best-known application of synthetic lethality involves drugs called PARP inhibitors used against cancers with BRCA1 or BRCA2 mutations. BRCA genes are responsible for a critical DNA repair process called homologous recombination, which fixes severe double-strand breaks in DNA. When BRCA genes are mutated (as they are in many breast and ovarian cancers), cells lose this repair ability but can still survive because other repair systems compensate.
PARP is a protein involved in one of those compensating systems. It helps fix minor single-strand DNA breaks. When you block PARP with a drug, those minor breaks accumulate and eventually turn into the severe double-strand breaks during cell division. In a healthy cell with working BRCA genes, the homologous recombination system handles these breaks easily. But in a BRCA-mutated cancer cell, there’s no backup. The double-strand breaks pile up, become irreparable, and the cell dies.
There’s an additional layer to this. PARP inhibitors don’t just stop the PARP protein from working. They also trap it onto the DNA, creating a physical obstruction that stalls the cell’s replication machinery. This trapped protein creates an even more toxic situation for BRCA-deficient cells, which lack the tools to clear these obstructions. Multiple PARP inhibitors have been approved and are now standard treatments for breast and ovarian cancers in patients whose tumors carry BRCA1 or BRCA2 mutations.
How Doctors Identify the Right Patients
Synthetic lethality only works when the cancer cell has the right vulnerability, so identifying that vulnerability is essential. For PARP inhibitor therapy, patients are tested for BRCA1 and BRCA2 mutations through genetic sequencing. This can be done through a blood test (which identifies inherited mutations) or through tumor testing (which can also catch mutations that arose spontaneously in the cancer itself).
Researchers are working to expand this approach beyond BRCA. Studies in lung cancer, for example, have identified protein markers that could predict which patients would benefit from synthetic lethality strategies targeting different gene pairs. The goal is to build a catalog of vulnerabilities: if a tumor has mutation X, drug Y should work against it. This makes synthetic lethality a cornerstone of precision medicine, where treatment is matched to the specific genetic profile of each patient’s cancer.
New Targets in Development
PARP inhibitors were the first synthetic lethality drugs approved for clinical use, but they won’t be the last. Several new targets are moving through clinical trials.
- ATR inhibitors target a protein that helps cells pause and repair DNA damage during replication. Multiple ATR inhibitors are in Phase I and Phase II clinical trials, showing promise in cancers that have specific DNA repair deficiencies.
- WEE1 inhibitors block a protein that acts as a checkpoint, preventing cells from dividing before their DNA is fully repaired. By removing this checkpoint in cells that already have other repair defects, the cancer cell is forced to divide with catastrophically damaged DNA.
- WRN inhibitors are among the newest class, targeting a protein involved in maintaining DNA stability. These are particularly promising for cancers with a specific type of genetic instability called microsatellite instability.
Each of these targets follows the same logic: find a repair or checkpoint system that cancer cells depend on more than healthy cells do, then block it.
How Researchers Find New Gene Pairs
Discovering which gene combinations are synthetically lethal requires testing thousands of possibilities. The current gold standard is genome-wide CRISPR screening. Researchers use CRISPR gene-editing tools to systematically disable individual genes across the entire genome in cancer cells that already carry a known mutation. If knocking out a gene kills the mutated cancer cells but not normal cells, that gene pair is a synthetic lethal candidate.
CRISPR screens have largely replaced older methods that used RNA interference, which was less precise and produced more false results. Newer variations of the technique can also turn genes up or down rather than fully disabling them, which helps researchers identify more subtle interactions. Combined with computational analysis, these screens are generating large databases of potential drug targets far faster than was previously possible.
Why Resistance Develops
The major limitation of synthetic lethality therapies is that cancers often find ways around them. A subset of patients with BRCA mutations don’t respond to PARP inhibitors from the start, and the majority of those who do respond eventually develop resistance.
The most common escape route is restoring the broken repair pathway. Cancer cells can acquire new mutations that partially reverse the original BRCA defect, re-enabling the homologous recombination system that the drug was designed to exploit. When that system comes back online, even partially, the synthetic lethal relationship breaks down and the drug stops working.
Cancer cells also rewire their internal signaling to shift which DNA repair pathways they rely on, effectively finding a third backup system. Beyond DNA repair, tumors can undergo metabolic changes under drug pressure, ramping up energy production and raw material synthesis to help cells survive the accumulated DNA damage. Some tumors increase their production of the molecular building blocks needed for DNA, essentially outrunning the damage the drug causes.
This is why combination strategies are a major area of research. Blocking two or three synthetic lethal targets simultaneously makes it much harder for cancer cells to develop resistance, because they would need to simultaneously restore or bypass multiple pathways at once.
Why It Matters for Cancer Treatment
Traditional chemotherapy poisons all rapidly dividing cells, which is why it causes side effects like hair loss and immune suppression. Synthetic lethality offers something fundamentally different: a way to target cancer cells based on their specific genetic flaws rather than their growth rate. Healthy cells, which don’t carry the relevant mutations, are largely unaffected.
This precision also opens a door for treating cancers driven by tumor suppressor genes like TP53 and BRCA1. These genes are frequently mutated in cancer, but you can’t fix a broken gene with a drug. What you can do is identify the synthetic lethal partner of that broken gene and target it instead. It’s an indirect attack, going after the vulnerability that the mutation creates rather than the mutation itself. For cancers that have long been considered “undruggable,” this approach represents one of the most practical paths forward.